Oncosia Scientific attended the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2026, held at the Los Angeles Convention Center, engaging with the North American nuclear medicine and radiopharmaceutical community across dosimetry, clinical trials, and emerging isotope programmes.
Discussions at the meeting spanned dosimetry across a range of clinically and developmentally relevant nuclides — ²²⁵Ac, ¹⁶¹Tb, ¹⁷⁷Lu, ¹³¹I, ⁶⁴Cu, and ²¹²Pb — drawing on Oncosia's experience across clinical trials and academic research collaborations.
The meeting also marked the formal launch of Oncosia's distributorship with Radnostix (formerly International Isotopes), bringing active reference and calibration sources to nuclear medicine departments across Germany.
Outstanding was the depth of engagement with radiopharmaceutical sponsors — reflecting a growing need for expert-led dosimetry service encompassing full end-to-end delivery: from technical operational manual design and site training & qualification, through to dosimetric analysis ready for regulatory submission.
Oncosia Scientific GmbH is a German-based specialist in dosimetry for nuclear medicine — providing patient-specific dosimetry services and software solutions for radioligand therapy, SIRT, and radiopharmaceutical trials. As authorised distributor of PLANET® Dose by DOSIsoft, and now of Radnostix calibration and reference products, Oncosia Scientific serves nuclear medicine departments, clinical trial sponsors, and CROs requiring expert-led dosimetry and the measurement infrastructure to support it. www.oncosia.de
Oncosia Scientific · June 2026